TBA Law Blog

Posted by: Katharine Heriges on Aug 17, 2018

The U.S. Department of Justice and the U.S. Drug Enforcement Administration announced yesterday that they will again recommend reducing the amount of more than 250 Schedule I and Schedule II controlled substances manufactured in the United States in 2019, for the third year in a row, Knoxnews reports. Among the drugs included in the reduction is fentanyl, a powerful opioid slated to be reduced by 12 percent in 2019, 48 percent overall.